Literature DB >> 18160515

Fitness of Streptococcus pneumoniae fluoroquinolone-resistant strains with topoisomerase IV recombinant genes.

Luz Balsalobre1, Adela G de la Campa.   

Abstract

The low prevalence of ciprofloxacin-resistant (Cp r) Streptococcus pneumoniae isolates carrying recombinant topoisomerase IV genes could be attributed to a fitness cost imposed by the horizontal transfer, which often implies the acquisition of larger-than-normal parE-parC intergenic regions. A study of the transcription of these genes and of the fitness cost for 24 isogenic Cp r strains was performed. Six first-level transformants were obtained either with PCR products containing the parC quinolone resistance-determining regions (QRDRs) of S. pneumoniae Cp r mutants with point mutations or with a PCR product that includes parE-QRDR-ant-parC-QRDR from a Cp r Streptococcus mitis isolate. The latter yielded two strains, T6 and T11, carrying parC-QRDR and parE-QRDR-ant-parC-QRDR, respectively. These first-level transformants were used as recipients in further transformations with the gyrA-QRDR PCR products to obtain 18 second-level transformants. In addition, strain Tr7 (which contains the GyrA E85K change) was used. Reverse transcription-PCR experiments showed that parE and parC were cotranscribed in R6, T6, and T11; and a single promoter located upstream of parE was identified in R6 by primer extension. The fitness of the transformants was estimated by pairwise competition with R6 in both one-cycle and two-cycle experiments. In the one-cycle experiments, most strains carrying the GyrA E85K change showed a fitness cost; the exception was recombinant T14. In the two-cycle experiments, a fitness cost was observed in most first-level transformants carrying the ParC changes S79F, S79Y, and D83Y and the GyrA E85K change; the exceptions were recombinants T6 and T11. The results suggest that there is no impediment due to a fitness cost for the spread of recombinant Cp r S. pneumoniae isolates, since some recombinants (T6, T11, and T14) exhibited an ability to compensate for the cost.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18160515      PMCID: PMC2258501          DOI: 10.1128/AAC.00731-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  45 in total

1.  Fluoroquinolone resistance in Streptococcus pneumoniae.

Authors:  J Liñares; A G de la Campa; R Pallares
Journal:  N Engl J Med       Date:  1999-11-11       Impact factor: 91.245

2.  Interspecies recombination contributes minimally to fluoroquinolone resistance in Streptococcus pneumoniae.

Authors:  D J Bast; J C de Azavedo; T Y Tam; L Kilburn; C Duncan; L A Mandell; R J Davidson; D E Low
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

3.  Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia.

Authors:  Ross Davidson; Rodrigo Cavalcanti; James L Brunton; Darrin J Bast; Joyce C S de Azavedo; Pamela Kibsey; Christine Fleming; Donald E Low
Journal:  N Engl J Med       Date:  2002-03-07       Impact factor: 91.245

4.  Quinolone-resistance mechanisms and in vitro susceptibility patterns among European isolates of Streptococcus mitis, Streptococcus sanguis, and Streptococcus pneumoniae.

Authors:  F J Schmitz; A Fisher; M Boos; S Mayer; D Milatovic; A C Fluit
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2001-03       Impact factor: 3.267

5.  Fluoroquinolones inhibit preferentially Streptococcus pneumoniae DNA topoisomerase IV than DNA gyrase native proteins.

Authors:  E Fernandez-Moreira; D Balas; I Gonzalez; A G de la Campa
Journal:  Microb Drug Resist       Date:  2000       Impact factor: 3.431

6.  Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999--2000, including a comparison of resistance rates since 1994--1995.

Authors:  G V Doern; K P Heilmann; H K Huynh; P R Rhomberg; S L Coffman; A B Brueggemann
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

7.  Interaction between DNA gyrase and quinolones: effects of alanine mutations at GyrA subunit residues Ser(83) and Asp(87).

Authors:  F M Barnard; A Maxwell
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

8.  Fluoroquinolone-resistant Streptococcus pneumoniae associated with levofloxacin therapy.

Authors:  C Urban; N Rahman; X Zhao; N Mariano; S Segal-Maurer; K Drlica; J J Rahal
Journal:  J Infect Dis       Date:  2001-08-09       Impact factor: 5.226

9.  Comparison of genetic divergence and fitness between two subclones of Helicobacter pylori.

Authors:  B Björkholm; A Lundin; A Sillén; K Guillemin; N Salama; C Rubio; J I Gordon; P Falk; L Engstrand
Journal:  Infect Immun       Date:  2001-12       Impact factor: 3.441

10.  Multiple modes of Escherichia coli DNA gyrase activity revealed by force and torque.

Authors:  Marcelo Nöllmann; Michael D Stone; Zev Bryant; Jeff Gore; Nancy J Crisona; Seok-Cheol Hong; Sylvain Mitelheiser; Anthony Maxwell; Carlos Bustamante; Nicholas R Cozzarelli
Journal:  Nat Struct Mol Biol       Date:  2007-03-04       Impact factor: 15.369

View more
  26 in total

1.  Fluoroquinolone efflux in Streptococcus suis is mediated by SatAB and not by SmrA.

Authors:  Jose Antonio Escudero; Alvaro San Millan; Belen Gutierrez; Laura Hidalgo; Roberto M La Ragione; Manal AbuOun; Marc Galimand; María José Ferrándiz; Lucas Domínguez; Adela G de la Campa; Bruno Gonzalez-Zorn
Journal:  Antimicrob Agents Chemother       Date:  2011-09-19       Impact factor: 5.191

Review 2.  Population biology of Gram-positive pathogens: high-risk clones for dissemination of antibiotic resistance.

Authors:  Rob J L Willems; William P Hanage; Debra E Bessen; Edward J Feil
Journal:  FEMS Microbiol Rev       Date:  2011-07-04       Impact factor: 16.408

3.  Nonoptimal DNA topoisomerases allow maintenance of supercoiling levels and improve fitness of Streptococcus pneumoniae.

Authors:  Luz Balsalobre; María José Ferrándiz; Gabriela de Alba; Adela G de la Campa
Journal:  Antimicrob Agents Chemother       Date:  2010-12-20       Impact factor: 5.191

4.  The genome of Streptococcus pneumoniae is organized in topology-reacting gene clusters.

Authors:  María-José Ferrándiz; Antonio J Martín-Galiano; Jorge B Schvartzman; Adela G de la Campa
Journal:  Nucleic Acids Res       Date:  2010-02-21       Impact factor: 16.971

Review 5.  The role of natural environments in the evolution of resistance traits in pathogenic bacteria.

Authors:  Jose L Martinez
Journal:  Proc Biol Sci       Date:  2009-04-08       Impact factor: 5.349

6.  Reactive Oxygen Species Contribute to the Bactericidal Effects of the Fluoroquinolone Moxifloxacin in Streptococcus pneumoniae.

Authors:  M J Ferrándiz; A J Martín-Galiano; C Arnanz; T Zimmerman; A G de la Campa
Journal:  Antimicrob Agents Chemother       Date:  2015-11-02       Impact factor: 5.191

7.  The fluoroquinolone levofloxacin triggers the transcriptional activation of iron transport genes that contribute to cell death in Streptococcus pneumoniae.

Authors:  María-José Ferrándiz; Adela G de la Campa
Journal:  Antimicrob Agents Chemother       Date:  2013-10-21       Impact factor: 5.191

8.  Characterization of recombinant fluoroquinolone-resistant pneumococcus-like isolates.

Authors:  Luz Balsalobre; Montserrat Ortega; Adela G de la Campa
Journal:  Antimicrob Agents Chemother       Date:  2012-10-31       Impact factor: 5.191

Review 9.  Biological and Epidemiological Features of Antibiotic-Resistant Streptococcus pneumoniae in Pre- and Post-Conjugate Vaccine Eras: a United States Perspective.

Authors:  Lindsay Kim; Lesley McGee; Sara Tomczyk; Bernard Beall
Journal:  Clin Microbiol Rev       Date:  2016-07       Impact factor: 26.132

10.  Changes in fluoroquinolone-resistant Streptococcus pneumoniae after 7-valent conjugate vaccination, Spain.

Authors:  Adela G de la Campa; Carmen Ardanuy; Luz Balsalobre; Emilio Pérez-Trallero; Jose M Marimón; Asunción Fenoll; Josefina Liñares
Journal:  Emerg Infect Dis       Date:  2009-06       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.